Personalis and Tempus Expand Collaboration to Biopharma

PSNL 12.16.2024

Full Press ReleaseSEC FilingsOur PSNL Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
  • 01.07.2025 - Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
  • 12.19.2024 - Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Recent Filings

  • 01.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 01.07.2025 - EX-99.1 EX-99.1
  • 01.07.2025 - 8-K Current report

Expanded collaboration to yield greater biopharma access to Personalis’ MRD solution

FREMONT, Calif.--(BUSINESS WIRE)--Dec. 16, 2024--Personalis, Inc.(Nasdaq: PSNL) andTempus AI, Inc.(Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed inNovember 2023to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024American Society of Clinical Oncology(ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis’ ultra-sensitive tumor-informed MRD product, NeXT Personal®Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors.

Following a positive reaction from the diagnostic market, the companies have agreed to expand their relationship to the biopharma industry. Under this expanded relationship, Tempus will be enabled to offer Personalis’ NeXT Personal MRD product to pharmaceutical and biotech customers who wish to bundle MRD testing with other Tempus offerings in a given study.

“While we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus’ integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products,” saidChris Hall, CEO ofPersonalis. “We believe the expansion of the relationship with Tempus will accelerate market penetration of our leading ultra-sensitive MRD platform and allow us to better capitalize on the opportunity.”

AboutPersonalis, Inc.

AtPersonalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.Personalisis based inFremont, California. To learn more, visitwww.personalis.comand connect with us onLinkedInandX, formerly known as Twitter.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are “forward-looking statements” within the meaning ofU.S.securities laws, including statements relating to the attributes of or opportunity for NeXT Personal or the expected benefits of the expanded relationship with Tempus. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the success of Tempus’ sales and marketing efforts, including the anticipated acceleration of the market penetration of NeXT Personal. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year endedDecember 31, 2023, filed with theSecurities and Exchange Commission(SEC) onFebruary 28, 2024, its Quarterly Report on Form 10-Q for the quarter endedMarch 31, 2024, filed with theSEConMay 8, 2024, its Quarterly Report on Form 10-Q for the quarter endedJune 30, 2024, filed with theSEConAugust 7, 2024, and its Quarterly Report on Form 10-Q for the quarter endedSeptember 30, 2024, filed with theSEConNovember 6, 2024. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof.Personalisundertakes no duty to update this information unless required by law.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241216417697/en/

Investors:Caroline Cornerinvestors@personalis.com415-202-5678

Media Contact:Patrick Schmidtpr@personalis.com630-290-2787

Source:Personalis, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com